NINDS 24-009009

Submitted by patelsnv on
Post Date/ Solicitation Issue Date
Closing Response Date
Proposed Award Date
Project Title
Olink Explore HT proteomic analysis of CSF from patients with ALS due to mutations in CHCHD10.
Contracting Office
National Institute of Neurological Disorders and Stroke (NINDS)

Contact Points

Primary Contract Specialist

ELAINE
ESTRELLA
elaine.estrella@nih.gov
NAICS Code Number
541380
Testing Laboratories and Services
Small Business Size Standard
OTSB - $19,000,000
FPDS Classification Code
Q301
Estimated Period of Performance
3 TO 6 MONTHS
Delivery of Goods
NINDS BLDG 35 RM 2A-211
Competition Status
Brand Name or Equal
Brand Name
PSOMAGEN
Rationale/ Salient Characteristics
The requested service must be performed using a platform that can detect greater than 1000 protein biomarkers from less than 100 uL of scarse Cerebral Spinal Fluid (CSF) samples from patients. The data must be comparable to that of collaborators that performed on the Olink Bioscience platform and to data from landmark studies such as a the UK Biobank which used to the Olink Bioscience platform. The site where the analysis is be performed must be local to allow delivery of precious patient samples without risk of loss in transport.
Single-Sole Source Determination
Market research shows that there are no other company that could compare data to collaborators within NIH and to leading biomarker studies worldwide, such as the UK biobank study , both of which have used Olink platform.
Background/Description of Requirement

The Inherited Movement Disorders investigates genetic causes neurological disorders that directly affect mitochondria. This includes a genetic form of Amythropic Lateral Schlerosis (ALS) that is caused by a mutation in CHCHD10. This requirement is needed to identify the protein composition of cerebral spinal fluid (CSF) samples from patients with this genetic form of ALS in order to identify protein biomarkers that may be useful for tracking disease progression and treatment response.

There is currently no treatment for ALS due to mutations in CHCHD10. A prerequisite for developing treatments is to identify protein biomarkers that may be monitored in biofluids like CSF that track with disease progression and treatment response. A technique for identifying this proteomic biomarkers is called proteomics. The industry leader is a platform called Olink Explore HT which can measure more than one thousand validated protein biomarkers from less than 100 uL of CSF sample. As CSF from patient samples is a precious resource it is critical that the platforms used be robust and provide the most data from a small amount of sample. The requested service is to perform 18 Olink Explore HT analysis on 18 CSF samples with a turnaround time of 5-7 weeks.

Interested parties may identify in writing their interest and capability in response to this requirement. Responses to this notice shall contain sufficient information to establish the interested parties’ bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.

All responses must be received by closing date and must reference the announcement. Responses may be submitted electronically to the attention of the contract specialist. Fax responses will not be accepted.

All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency.